KF 13218

Cat. No.:	HY-U00231
CAS No.:	127654-03-9
Molecular Formula:	$C_{20}H_{20}N_2O_3$
Molecular Weight:	336.38
Target:	Prostaglandin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	KF 13218 is a potent, selective and long lasting thromboxane B2 (TXB2) synthase inhibitor with an IC_{50} value of 5.3±1.3 nM.
IC_{50} & Target	TXB_2 5.3 nM (IC_{50})
In Vitro	KF 13218 inhibits human and bovine platelet thromboxane synthase with IC_{50} values of 27±5.8 nM (mean±S.E.M.) and 36±6.9 nM, respectively. KF 13218 does not inhibit cyclooxygenase or 5-lipoxygenase up to a dose of 100 μM and does not antagonize thromboxane A2/prostaglandin H2 receptors. KF 13218 inhibits arachidonic acid-induced thromboxane B2 production by human intact platelets with an IC_{50} value of 5.3±1.3 nM. The IC_{50} value of KF 13218 for the intact platelets is about 5 times lower than that for the microsomal enzyme. The inhibition of thromboxane synthase in platelets by KF 13218 is sustained after removal of the extracellular compound[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	After oral dosing in rat from 0.03 mg/kg to 3 mg/kg, KF 13218 dose-dependently inhibits the thromboxane B2 production in serum, and the inhibition is retained for 72 h. KF 13218, at a dose of 0.1 mg/kg p.o. prevents mortality induced by sodium arachidonate in rabbit[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Miki I, et al. A novel pyridobenzazepinone derivative with long lasting thromboxane synthase inhibition. Arzneimittelforschung. 1995 Oct;45(10):1066-70.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA